Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Dec 1;6(12):e2347511.
doi: 10.1001/jamanetworkopen.2023.47511.

Age-Related Incidence and Peak Occurrence of Contralateral Breast Cancer

Hakyoung Kim  1   2 , Tae In Yoon  3 , Seonok Kim  4 , Sae Byul Lee  1 , Jisun Kim  1 , Il Yong Chung  1 , Beom Seok Ko  1 , Jong Won Lee  1 , Byung Ho Son  1 , Young Jin Lee  1 , Sungchan Gwark  5 , Hee Jeong Kim  1
Affiliations

Age-Related Incidence and Peak Occurrence of Contralateral Breast Cancer

Hakyoung Kim et al. JAMA Netw Open. .

Abstract

Importance: Young patients with breast cancer have higher risk for developing contralateral breast cancer (CBC) and have epidemiologic characteristics different from those of older patients.

Objective: To examine the incidence and peak occurrence of CBC according to age at primary breast cancer (PBC) surgery.

Design, setting, and participants: This cohort study included patients who were diagnosed with and underwent surgery for unilateral nonmetastatic breast cancer at Asan Medical Center, Korea, between January 1, 1999, and December 31, 2013, with follow-up through December 31, 2018. Data were analyzed from December 1, 2021, through April 30, 2023. Patients were divided into 2 groups according to their age at surgery for PBC: younger (≤35 years) vs older (>35 years).

Main outcomes and measures: The main outcomes were cumulative incidence and hazard rate of CBC in the entire study population and in subgroups divided by cancer subtype, categorized according to hormone receptor (HR) and ERBB2 status.

Results: A total of 16 251 female patients with stage 0 to III breast cancer were analyzed; all patients were Korean. The mean (SD) age was 48.61 (10.06) years; 1318 patients (8.11%) were in the younger group, and 14 933 (91.89%) were in the older group. Median follow-up was 107 months (IQR, 79-145 months). Compared with the older group, the younger group had significantly higher incidence of CBC (10-year cumulative incidence, 7.1% vs 2.9%; P < .001) and higher risk (hazard ratio, 2.10; 95% CI, 1.62-2.74) of developing CBC. The hazard rate, which indicates risk for developing CBC at a certain time frame, differed according to the subtype of primary cancer. In patients with the HR+/ERBB2- subtype, the risk increased continuously in both age groups. In patients with the triple negative subtype, the risk increased until approximately 10 years and then decreased in both age groups. Meanwhile, in the HR-/ERBB2+ subtype, risk peaked earlier, especially in the younger group (1.7 years since first surgery in the younger group and 4.8 years in the older group).

Conclusions and relevance: In this cohort study, patients aged 35 years or younger with breast cancer had a higher risk of developing CBC than older patients. Moreover, young patients with the HR-/ERBB2+ subtype tended to have a shorter interval for developing CBC. These findings might be useful in guiding treatment decisions, such as contralateral prophylactic mastectomy.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: None reported.

Figures

Figure 1.
Figure 1.. Study Population
AMC indicates Asan Medical Center; CBC, contralateral breast cancer.
Figure 2.
Figure 2.. Cumulative Incidence of Developing Contralateral Breast Cancer (CBC) According to Age in All Patients and in Subgroup Analysis by Subtype
HR indicates hormone receptor.
Figure 3.
Figure 3.. Hazard Rate for Developing Contralateral Breast Cancer (CBC) According to Age in All Patients and in Subgroup Analysis by Subtype
HR indicates hormone receptor.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Rosenberg PS, Barker KA, Anderson WF. Estrogen receptor status and the future burden of invasive and in situ breast cancers in the United States. J Natl Cancer Inst. 2015;107(9):djv159. doi:10.1093/jnci/djv159 - DOI - PMC - PubMed
    1. Spronk I, Schellevis FG, Burgers JS, de Bock GH, Korevaar JC. Incidence of isolated local breast cancer recurrence and contralateral breast cancer: a systematic review. Breast. 2018;39:70-79. doi:10.1016/j.breast.2018.03.011 - DOI - PubMed
    1. Akdeniz D, Schmidt MK, Seynaeve CM, et al. . Risk factors for metachronous contralateral breast cancer: a systematic review and meta-analysis. Breast. 2019;44:1-14. doi:10.1016/j.breast.2018.11.005 - DOI - PubMed
    1. Reiner AS, John EM, Brooks JD, et al. . Risk of asynchronous contralateral breast cancer in noncarriers of BRCA1 and BRCA2 mutations with a family history of breast cancer: a report from the Women’s Environmental Cancer and Radiation Epidemiology Study. J Clin Oncol. 2013;31(4):433-439. doi:10.1200/JCO.2012.43.2013 - DOI - PMC - PubMed
    1. Kurian AW, McClure LA, John EM, Horn-Ross PL, Ford JM, Clarke CA. Second primary breast cancer occurrence according to hormone receptor status. J Natl Cancer Inst. 2009;101(15):1058-1065. doi:10.1093/jnci/djp181 - DOI - PMC - PubMed

Publication types